PMID- 34336283
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2090-1852 (Print)
IS  - 2090-1860 (Electronic)
IS  - 2090-1860 (Linking)
VI  - 2021
DP  - 2021
TI  - Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the 
      Treatment of Relapsing-Remitting Multiple Sclerosis.
PG  - 6679197
LID - 10.1155/2021/6679197 [doi]
LID - 6679197
AB  - BACKGROUND: The aim of this observational study is to investigate the efficacy 
      and safety of two approved oral disease-modifying therapies (DMTs) in patients 
      with remitting-relapsing multiple sclerosis (RRMS): dimethyl fumarate (DMF) vs. 
      teriflunomide (TRF). METHODS: A total of 159 RRMS patients (82 on TRF and 77 on 
      DMF) were included. The expanded disability status scale (EDSS), confirmed 
      disability improvement (CDI), confirmed disability progression (CDP), and 
      annualized relapse rate (ARR) were evaluated for the two-year period prior to 
      enrollment in our study. The drug-associated adverse effects (AEs) were recorded. 
      We conducted propensity matching score to compare the efficacy between TRF and 
      DMF. RESULTS: After matching for the confounders, TRF- and DMF-treated groups 
      were not different in terms of EDSS (P value = 0.54), CDI (P value = 0.80), CDP 
      (P value = 0.39), and ARR (P value >0.05). TRF discontinuation occurred in 2 
      patients (2.43%) due to mediastinitis and liver dysfunction, while a patient 
      (1.29%) discontinued DMF due to depression. Incidence rate of AEs in the 
      TRF-treated group was 81.4%: hair thinning (hair loss) (62.9%), nail loss 
      (20.9%), and elevated aminotransferase (14.8%) were the most common AEs; in 
      DMF-treated patients, AEs were 88.2% with predominance of flushing (73.2%), 
      pruritus (16.9%), and abdominal pain (16.9%). CONCLUSION: Based on our findings, 
      DMF is as efficacious and safe as TRF for the treatment of RRMS in our Iranian 
      study population. Multicentric studies need to corroborate these findings in 
      other populations.
CI  - Copyright (c) 2021 Nasim Nehzat et al.
FAU - Nehzat, Nasim
AU  - Nehzat N
AUID- ORCID: 0000-0003-1265-1663
AD  - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, 
      Isfahan, Iran.
AD  - Universal Council of Epidemiology (UCE), Universal Scientific Education and 
      Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
FAU - Mirmosayyeb, Omid
AU  - Mirmosayyeb O
AUID- ORCID: 0000-0002-3756-2985
AD  - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, 
      Isfahan, Iran.
AD  - Universal Council of Epidemiology (UCE), Universal Scientific Education and 
      Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
AD  - Department of Neurology, School of Medicine, Isfahan University of Medical 
      Sciences, Isfahan, Iran.
FAU - Barzegar, Mahdi
AU  - Barzegar M
AUID- ORCID: 0000-0002-6578-0250
AD  - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, 
      Isfahan, Iran.
AD  - Department of Neurology, School of Medicine, Isfahan University of Medical 
      Sciences, Isfahan, Iran.
FAU - Vosoughi, Reza
AU  - Vosoughi R
AUID- ORCID: 0000-0002-2337-1088
AD  - University of Toronto, St. Michael's Hospital Multiple Sclerosis Clinic, Toronto, 
      Ontario, Canada.
FAU - Fazeli, Erfane
AU  - Fazeli E
AUID- ORCID: 0000-0003-2192-0984
AD  - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, 
      Isfahan, Iran.
FAU - Shaygannejad, Vahid
AU  - Shaygannejad V
AUID- ORCID: 0000-0002-9732-4153
AD  - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, 
      Isfahan, Iran.
AD  - Department of Neurology, School of Medicine, Isfahan University of Medical 
      Sciences, Isfahan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20210715
PL  - United States
TA  - Neurol Res Int
JT  - Neurology research international
JID - 101543314
PMC - PMC8298169
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/08/03 06:00
MHDA- 2021/08/03 06:01
PMCR- 2021/07/15
CRDT- 2021/08/02 06:02
PHST- 2021/01/02 00:00 [received]
PHST- 2021/06/26 00:00 [revised]
PHST- 2021/07/08 00:00 [accepted]
PHST- 2021/08/02 06:02 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/08/03 06:01 [medline]
PHST- 2021/07/15 00:00 [pmc-release]
AID - 10.1155/2021/6679197 [doi]
PST - epublish
SO  - Neurol Res Int. 2021 Jul 15;2021:6679197. doi: 10.1155/2021/6679197. eCollection 
      2021.